Immutep (IMMP) Times Interest Earned (2015 - 2024)
Immutep's (IMMP) quarterly Times Interest Earned came in at -$143.84 in Q2 2016, down 460968266.54% YoY from N/an in Q3 2015, and down 460968266.54% on a QoQ basis from $0.0 in Q2 2015.
Immutep (IMMP) Times Interest Earned (2015 - 2024) Analysis & Trends
Immutep (IMMP) has 2 years of Times Interest Earned data on file, last reported at -$143.84 in Q2 2016.
- Quarterly Times Interest Earned fell 460968266.54% year-over-year to -$143.84 in Q2 2016, while the trailing twelve-month figure through Jun 2017 was -$739.94 (down 981035.7% YoY) and the FY2025 annual result came in at -$1655.9, down 8.81% from the prior year.
- Times Interest Earned eased to -$143.84 in Q2 2016, from $0.0 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $0.0 in Q2 2015 to a low of -$143.84 in Q2 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Immutep | 56.46 Mn | -8.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 0.00 |
| Jun 30, 2024 | 205.55 |
| Dec 31, 2023 | 179.55 |
| Dec 31, 2022 | 187.74 |
| Dec 31, 2021 | 172.97 |
| Dec 31, 2019 | 113.08 |
| Jun 30, 2016 | -143.84 |
| Jun 30, 2015 | 0.00 |